Pneumococcal Vaccines in China

Overview

Journal Hum Vaccin Immunother

Date 2025 Jan 30

PMID 39882709

Authors

Shanshan Wang

Bin Li

Qiong Chen

Chune Wang

Bin Wang

Qiang Ye

Yinghua Xu

Affiliations

Soon will be listed here.

Abstract

Invasive pneumococcal disease (IPD) is a serious global public health problem and the leading cause of morbidity and mortality in children and adults in China. Thus, developing and administering pneumococcal vaccines are important for disease prevention. The PPV23 and PCV13 vaccines are available in the Chinese market and are primarily produced by domestic manufacturers. The potential risk of increased IPD caused by non-vaccine serotypes should be considered. Here, we review the current status of IPD, pneumococcal vaccines, and their quality control in China. We also address the challenges and future directions for making progress in controlling IPD, emphasizing the need for further evaluation of the disease burden and monitoring the effectiveness of vaccination efforts.

References

Liu Y, Chen M, Zhao T, Wang H, Wang R, Liu Q . [A multicentre study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China]. Zhonghua Jie He He Hu Xi Za Zhi. 2006; 29(1):3-8. View

Wang B, Lin W, Qian C, Zhang Y, Zhao G, Wang W . Disease Burden of Meningitis Caused by Streptococcus pneumoniae Among Under-Fives in China: A Systematic Review and Meta-analysis. Infect Dis Ther. 2023; 12(11):2567-2580. PMC: 10651812. DOI: 10.1007/s40121-023-00878-y. View

McDaniel L, McDaniel D, Hollingshead S, Briles D . Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun. 1998; 66(10):4748-54. PMC: 108585. DOI: 10.1128/IAI.66.10.4748-4754.1998. View

Wang Y, Shi G, Wang X, Xie Z, Gou J, Huang L . Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18-49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study. Vaccines (Basel). 2024; 12(8). PMC: 11358999. DOI: 10.3390/vaccines12080827. View

Wahl B, OBrien K, Greenbaum A, Majumder A, Liu L, Chu Y . Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018; 6(7):e744-e757. PMC: 6005122. DOI: 10.1016/S2214-109X(18)30247-X. View

Lu Y, Leite L, Goncalves V, Dias W, Liberman C, Fratelli F . GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine. 2010; 28(47):7468-75. PMC: 2981440. DOI: 10.1016/j.vaccine.2010.09.031. View

Huang B . The new China vaccine administration law: Re-establishing confidence in vaccines. Biologicals. 2019; 61:95-96. DOI: 10.1016/j.biologicals.2019.08.007. View

Hausdorff W, Siber G, Paradiso P . Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet. 2001; 357(9260):950-2. DOI: 10.1016/S0140-6736(00)04222-7. View

Liang Q, Li H, Chang X, Zhang H, Hao H, Ye Q . A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old. Vaccine. 2021; 39(47):6947-6955. DOI: 10.1016/j.vaccine.2021.09.047. View

10.

Mangen M, Rozenbaum M, Huijts S, van Werkhoven C, Postma D, Atwood M . Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015; 46(5):1407-16. PMC: 4750466. DOI: 10.1183/13993003.00325-2015. View

11.

Kong Y, Zhang W, Jiang Z, Wang L, Li C, Li Y . Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial. Hum Vaccin Immunother. 2015; 11(10):2425-33. PMC: 4635697. DOI: 10.1080/21645515.2015.1055429. View

12.

. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1151-1210. PMC: 5605883. DOI: 10.1016/S0140-6736(17)32152-9. View

13.

Yu Y, Xie X, Ren L, Deng Y, Gao Y, Zhang Y . Epidemiological characteristics of nasopharyngeal Streptococcus pneumoniae strains among children with pneumonia in Chongqing, China. Sci Rep. 2019; 9(1):3324. PMC: 6397308. DOI: 10.1038/s41598-019-40088-6. View

14.

Briles D, Hollingshead S, King J, Swift A, Braun P, Park M . Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis. 2000; 182(6):1694-701. DOI: 10.1086/317602. View

15.

Leroux-Roels G, Maes C, De Boever F, Traskine M, Ruggeberg J, Borys D . Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study. Vaccine. 2014; 32(50):6838-46. DOI: 10.1016/j.vaccine.2014.02.052. View

16.

Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X . Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. Clin Infect Dis. 2021; 75(3):390-398. PMC: 9427137. DOI: 10.1093/cid/ciab990. View

17.

Lyu Z, Li J, Zhen J, Shi W, Meng Q, Zhou W . A Hospital-Based and Cross-Sectional Investigation on Clinical Characteristics of Pediatric Isolates in Beijing from 2015 to 2021. Infect Drug Resist. 2023; 16:499-508. PMC: 9885871. DOI: 10.2147/IDR.S398549. View

18.

Bonten M, Huijts S, Bolkenbaas M, Webber C, Patterson S, Gault S . Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372(12):1114-25. DOI: 10.1056/NEJMoa1408544. View

19.

Robbins J, Austrian R, Lee C, Rastogi S, Schiffman G, HENRICHSEN J . Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis. 1983; 148(6):1136-59. DOI: 10.1093/infdis/148.6.1136. View

20.

Goncalves V, Dias W, Campos I, Liberman C, Sbrogio-Almeida M, Silva E . Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability. Vaccine. 2013; 32(9):1113-20. DOI: 10.1016/j.vaccine.2013.10.091. View